Poland· PL-100502426
Cejemly
A sugemalimab product containing sugemalimabum, registered in Poland by CStone Pharmaceuticals Ireland Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sugemalimab is registered in 7 of 19 countries.
Countries holding a registration under ATC L01FF11 (sugemalimab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Sugemalimab · ATC L01FF11
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Sugemalimabum
- Manufacturer
- CStone Pharmaceuticals Ireland Limited
- Country
- Poland (PL)
- ATC code
- L01FF11
- ATC class
- Sugemalimab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin06974201630097
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sugemalimab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCejemly 600 mgSfl Pharmaceuticals Deutschland
- CzechiaCEJEMLYCStone Pharmaceuticals Ireland Limited, Dublin 1
- SpainCEJEMLY 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONCstone Pharmaceuticals Ireland Limited
- FinlandCejemlyCstone Pharmaceuticals Ireland Limited
- IrelandCejemly 600 mg concentrate for solution for infusionCstone Pharmaceuticals Ireland Limited
- IcelandCejemlyCstone Pharmaceuticals Ireland Limited
- NetherlandsCejemly 600 mg concentraat voor oplossing voor infusieCStone Pharmaceuticals Ireland Limited
- SwedenCejemly 600 mg Koncentrat till infusionsvätska, lösningCStone Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cejemly
- Liechtenstein · Cejemly
- Norway · Cejemly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcef03d6-dbfc-4ded-8f5f-64150f53bd90 GET /v1/drugs/bcef03d6-dbfc-4ded-8f5f-64150f53bd90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "600 mg (30 mg/ml)",
"packaging": "06974201630097 ¦ Rpz ¦ EU/1/24/1833/001 ¦ 157512\n2 fiol. 20 ml",
"substance": "Sugemalimabum 600 mg",
"common_name": "Sugemalimabum",
"pl_product_id": "100502426",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sugemalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.